Laboratory pipette with drop of liquid over glass test tubes in a science research lab

22 September 2020 - interim results

The AIM-listed international healthcare group Alliance Pharma has announced its interim results to 30 June and these have shown a resilient performance given the effect of the pandemic.  Revenues for the period declined by 7% to £65.3m with adjusted pre-tax profits rising by 7% to £16.3m.  Earnings per share on the same basis were 5% higher at 2.45p and the interim dividend was maintained at 0.536p.  There was a relatively strong performance in the consumer brands division, which includes names such as Kelo-cote for scar prevention and treatment . . .

This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.

Already a member, log in HERE.